Literature references. 2 Emos G. et al., Efficacy and safety of AEZS-108 (INN: Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago- study group (AGO GYN 5), Gynecol Oncol 2014 Jun, 133 (3): 427-32 3 Emons G, ▇▇▇▇▇ S, ▇▇▇▇▇▇ P, ▇▇▇▇▇▇▇ J, Wimberger P, ▇▇▇▇▇▇▇ A, ▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇ F, ▇▇▇▇ P, Gruendker C, AGO Study Group. Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor- positive platinum resistant ovarian cancer. J Clin Oncol 2010 ASCO Annual Meeting Proceedings;28(15s):abstract 5035.
Appears in 1 contract
Literature references. 2 Emos G. et al., Efficacy and safety of AEZS-108 (INN: Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago- ago-study group (AGO GYN 5), Gynecol Oncol 2014 Jun, 133 (3): 427-32 3 Emons G, ▇▇▇▇▇ Tomov S, ▇▇▇▇▇▇ P, ▇▇▇▇▇▇▇ Sehouli J, Wimberger P, ▇▇▇▇▇▇▇ A, ▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇ F, ▇▇▇▇ P, Gruendker C, AGO Study Group. Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor- receptor-positive platinum resistant ovarian cancer. J Clin Oncol 2010 ASCO Annual Meeting Proceedings;28(15s):abstract 5035.
Appears in 1 contract
Sources: Technology Transfer and Technical Assistance Agreement (Aeterna Zentaris Inc.)